CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus nab-paclitaxel in 37 patients with TNBC, whose tumor...
Phase 2
Milano, Italy and 2 other locations
with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...
Phase 3
Milano, Lombardia, Italy and 75 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Milano, Lombardia, Italy and 199 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Milano, Italy and 228 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Milano, Italy and 516 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Milano, Lombardia, Italy and 108 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Milano, Italy and 505 other locations
to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...
Phase 3
Milano, Lombardia, Italy and 117 other locations
vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...
Phase 3
Milano, Italy and 192 other locations
platinum-resistant ovarian cancer. This cohort will be made up of 20 evaluable patients, 10 per arm....
Phase 1
Milano, Italy and 6 other locations
Clinical trials
Research sites
Resources
Legal